nodes	percent_of_prediction	percent_of_DWPC	metapath
Dobutamine—CA5A—female reproductive system—urinary bladder cancer	0.0314	0.104	CbGeAlD
Dobutamine—Phlebitis—Carboplatin—urinary bladder cancer	0.029	0.0625	CcSEcCtD
Dobutamine—Skin necrosis—Cisplatin—urinary bladder cancer	0.0289	0.0622	CcSEcCtD
Dobutamine—COMT—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0271	0.116	CbGpPWpGaD
Dobutamine—Skin necrosis—Etoposide—urinary bladder cancer	0.0265	0.057	CcSEcCtD
Dobutamine—CA5B—prostate gland—urinary bladder cancer	0.0223	0.0739	CbGeAlD
Dobutamine—COMT—prostate gland—urinary bladder cancer	0.0206	0.068	CbGeAlD
Dobutamine—ADRB1—prostate gland—urinary bladder cancer	0.0174	0.0576	CbGeAlD
Dobutamine—COMT—seminal vesicle—urinary bladder cancer	0.0174	0.0575	CbGeAlD
Dobutamine—Skin necrosis—Methotrexate—urinary bladder cancer	0.0158	0.0341	CcSEcCtD
Dobutamine—CA5B—urethra—urinary bladder cancer	0.0149	0.0494	CbGeAlD
Dobutamine—Skin necrosis—Epirubicin—urinary bladder cancer	0.0148	0.032	CcSEcCtD
Dobutamine—COMT—smooth muscle tissue—urinary bladder cancer	0.0146	0.0482	CbGeAlD
Dobutamine—COMT—renal system—urinary bladder cancer	0.014	0.0464	CbGeAlD
Dobutamine—Chest pain—Valrubicin—urinary bladder cancer	0.0138	0.0298	CcSEcCtD
Dobutamine—COMT—urethra—urinary bladder cancer	0.0138	0.0455	CbGeAlD
Dobutamine—Skin necrosis—Doxorubicin—urinary bladder cancer	0.0137	0.0296	CcSEcCtD
Dobutamine—COMT—Dopamine metabolism—NQO1—urinary bladder cancer	0.0136	0.058	CbGpPWpGaD
Dobutamine—CA2—prostate gland—urinary bladder cancer	0.0128	0.0423	CbGeAlD
Dobutamine—Skin exfoliation—Thiotepa—urinary bladder cancer	0.0123	0.0265	CcSEcCtD
Dobutamine—CA5B—female reproductive system—urinary bladder cancer	0.0122	0.0403	CbGeAlD
Dobutamine—COMT—female reproductive system—urinary bladder cancer	0.0112	0.0371	CbGeAlD
Dobutamine—CA5B—vagina—urinary bladder cancer	0.011	0.0365	CbGeAlD
Dobutamine—CA2—seminal vesicle—urinary bladder cancer	0.0108	0.0358	CbGeAlD
Dobutamine—COMT—Estrogen metabolism—NQO1—urinary bladder cancer	0.0104	0.0447	CbGpPWpGaD
Dobutamine—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.0103	0.0223	CcSEcCtD
Dobutamine—COMT—vagina—urinary bladder cancer	0.0101	0.0336	CbGeAlD
Dobutamine—Skin exfoliation—Cisplatin—urinary bladder cancer	0.00963	0.0208	CcSEcCtD
Dobutamine—ADRB1—female reproductive system—urinary bladder cancer	0.00951	0.0315	CbGeAlD
Dobutamine—CA2—epithelium—urinary bladder cancer	0.00939	0.0311	CbGeAlD
Dobutamine—Pruritus—Valrubicin—urinary bladder cancer	0.00937	0.0202	CcSEcCtD
Dobutamine—CA2—smooth muscle tissue—urinary bladder cancer	0.00904	0.0299	CbGeAlD
Dobutamine—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00894	0.0193	CcSEcCtD
Dobutamine—Skin exfoliation—Etoposide—urinary bladder cancer	0.00882	0.019	CcSEcCtD
Dobutamine—COMT—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00877	0.0375	CbGpPWpGaD
Dobutamine—CA2—renal system—urinary bladder cancer	0.00871	0.0288	CbGeAlD
Dobutamine—Phlebitis—Cisplatin—urinary bladder cancer	0.0085	0.0183	CcSEcCtD
Dobutamine—COMT—Phase II conjugation—GSTO2—urinary bladder cancer	0.00832	0.0356	CbGpPWpGaD
Dobutamine—COMT—Phase II conjugation—NAT1—urinary bladder cancer	0.00832	0.0356	CbGpPWpGaD
Dobutamine—Headache—Valrubicin—urinary bladder cancer	0.0083	0.0179	CcSEcCtD
Dobutamine—Dyspnoea—Mitomycin—urinary bladder cancer	0.00814	0.0175	CcSEcCtD
Dobutamine—COMT—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00801	0.0343	CbGpPWpGaD
Dobutamine—Nausea—Valrubicin—urinary bladder cancer	0.00787	0.017	CcSEcCtD
Dobutamine—Phlebitis—Etoposide—urinary bladder cancer	0.00779	0.0168	CcSEcCtD
Dobutamine—COMT—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00761	0.0325	CbGpPWpGaD
Dobutamine—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.00715	0.0154	CcSEcCtD
Dobutamine—CA5B—lymph node—urinary bladder cancer	0.00713	0.0236	CbGeAlD
Dobutamine—CA2—female reproductive system—urinary bladder cancer	0.00697	0.0231	CbGeAlD
Dobutamine—Hypokalaemia—Cisplatin—urinary bladder cancer	0.00667	0.0144	CcSEcCtD
Dobutamine—COMT—lymph node—urinary bladder cancer	0.00656	0.0217	CbGeAlD
Dobutamine—Angina pectoris—Fluorouracil—urinary bladder cancer	0.0065	0.014	CcSEcCtD
Dobutamine—CA2—vagina—urinary bladder cancer	0.00631	0.0209	CbGeAlD
Dobutamine—Ventricular extrasystoles—Epirubicin—urinary bladder cancer	0.00574	0.0124	CcSEcCtD
Dobutamine—Headache—Mitomycin—urinary bladder cancer	0.00572	0.0123	CcSEcCtD
Dobutamine—Nausea—Mitomycin—urinary bladder cancer	0.00542	0.0117	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Doxorubicin—urinary bladder cancer	0.00531	0.0114	CcSEcCtD
Dobutamine—Skin exfoliation—Methotrexate—urinary bladder cancer	0.00529	0.0114	CcSEcCtD
Dobutamine—COMT—Biological oxidations—GSTZ1—urinary bladder cancer	0.00513	0.0219	CbGpPWpGaD
Dobutamine—COMT—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00506	0.0216	CbGpPWpGaD
Dobutamine—Skin exfoliation—Epirubicin—urinary bladder cancer	0.00495	0.0107	CcSEcCtD
Dobutamine—COMT—Biological oxidations—GSTO2—urinary bladder cancer	0.00486	0.0208	CbGpPWpGaD
Dobutamine—COMT—Biological oxidations—NAT1—urinary bladder cancer	0.00486	0.0208	CbGpPWpGaD
Dobutamine—COMT—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.0048	0.0205	CbGpPWpGaD
Dobutamine—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.00458	0.00986	CcSEcCtD
Dobutamine—COMT—Phase II conjugation—NAT2—urinary bladder cancer	0.00456	0.0195	CbGpPWpGaD
Dobutamine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00449	0.00969	CcSEcCtD
Dobutamine—Tachycardia—Thiotepa—urinary bladder cancer	0.00448	0.00966	CcSEcCtD
Dobutamine—COMT—Biological oxidations—UGT2B7—urinary bladder cancer	0.00445	0.019	CbGpPWpGaD
Dobutamine—COMT—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00439	0.0188	CbGpPWpGaD
Dobutamine—Phlebitis—Epirubicin—urinary bladder cancer	0.00437	0.00941	CcSEcCtD
Dobutamine—CA2—lymph node—urinary bladder cancer	0.00408	0.0135	CbGeAlD
Dobutamine—Phlebitis—Doxorubicin—urinary bladder cancer	0.00404	0.00871	CcSEcCtD
Dobutamine—Chest pain—Gemcitabine—urinary bladder cancer	0.00403	0.00868	CcSEcCtD
Dobutamine—COMT—Biological oxidations—CYP4B1—urinary bladder cancer	0.00401	0.0171	CbGpPWpGaD
Dobutamine—Chest pain—Fluorouracil—urinary bladder cancer	0.00396	0.00854	CcSEcCtD
Dobutamine—COMT—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00395	0.0169	CbGpPWpGaD
Dobutamine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00378	0.00815	CcSEcCtD
Dobutamine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00372	0.00801	CcSEcCtD
Dobutamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00371	0.00799	CcSEcCtD
Dobutamine—COMT—Phase II conjugation—HPGDS—urinary bladder cancer	0.00364	0.0156	CbGpPWpGaD
Dobutamine—Hypotension—Gemcitabine—urinary bladder cancer	0.00361	0.00778	CcSEcCtD
Dobutamine—Hypotension—Fluorouracil—urinary bladder cancer	0.00355	0.00765	CcSEcCtD
Dobutamine—COMT—Phase II conjugation—GSTT1—urinary bladder cancer	0.00353	0.0151	CbGpPWpGaD
Dobutamine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00352	0.0076	CcSEcCtD
Dobutamine—Tachycardia—Cisplatin—urinary bladder cancer	0.00351	0.00757	CcSEcCtD
Dobutamine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00344	0.00742	CcSEcCtD
Dobutamine—Chest pain—Etoposide—urinary bladder cancer	0.00344	0.00741	CcSEcCtD
Dobutamine—Hypokalaemia—Epirubicin—urinary bladder cancer	0.00342	0.00738	CcSEcCtD
Dobutamine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00339	0.0073	CcSEcCtD
Dobutamine—Hypotension—Cisplatin—urinary bladder cancer	0.00336	0.00725	CcSEcCtD
Dobutamine—Pruritus—Thiotepa—urinary bladder cancer	0.00325	0.007	CcSEcCtD
Dobutamine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00323	0.00696	CcSEcCtD
Dobutamine—Tachycardia—Etoposide—urinary bladder cancer	0.00322	0.00694	CcSEcCtD
Dobutamine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00321	0.00692	CcSEcCtD
Dobutamine—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.00317	0.00683	CcSEcCtD
Dobutamine—Angina pectoris—Epirubicin—urinary bladder cancer	0.00317	0.00682	CcSEcCtD
Dobutamine—Hypotension—Etoposide—urinary bladder cancer	0.00308	0.00664	CcSEcCtD
Dobutamine—Dyspnoea—Etoposide—urinary bladder cancer	0.00294	0.00634	CcSEcCtD
Dobutamine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00293	0.00631	CcSEcCtD
Dobutamine—Headache—Thiotepa—urinary bladder cancer	0.00288	0.0062	CcSEcCtD
Dobutamine—Pruritus—Gemcitabine—urinary bladder cancer	0.00273	0.00589	CcSEcCtD
Dobutamine—Nausea—Thiotepa—urinary bladder cancer	0.00273	0.00588	CcSEcCtD
Dobutamine—Pruritus—Fluorouracil—urinary bladder cancer	0.00269	0.00579	CcSEcCtD
Dobutamine—COMT—Biological oxidations—NAT2—urinary bladder cancer	0.00267	0.0114	CbGpPWpGaD
Dobutamine—COMT—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00263	0.0112	CbGpPWpGaD
Dobutamine—COMT—Phase II conjugation—GSTP1—urinary bladder cancer	0.00245	0.0105	CbGpPWpGaD
Dobutamine—Headache—Gemcitabine—urinary bladder cancer	0.00242	0.00521	CcSEcCtD
Dobutamine—Headache—Fluorouracil—urinary bladder cancer	0.00238	0.00513	CcSEcCtD
Dobutamine—Pruritus—Etoposide—urinary bladder cancer	0.00233	0.00503	CcSEcCtD
Dobutamine—Nausea—Gemcitabine—urinary bladder cancer	0.00229	0.00494	CcSEcCtD
Dobutamine—Nausea—Fluorouracil—urinary bladder cancer	0.00226	0.00486	CcSEcCtD
Dobutamine—COMT—Phase II conjugation—GSTM1—urinary bladder cancer	0.00225	0.00962	CbGpPWpGaD
Dobutamine—Nausea—Cisplatin—urinary bladder cancer	0.00214	0.00461	CcSEcCtD
Dobutamine—COMT—Biological oxidations—HPGDS—urinary bladder cancer	0.00213	0.00911	CbGpPWpGaD
Dobutamine—COMT—Biological oxidations—GSTT1—urinary bladder cancer	0.00207	0.00884	CbGpPWpGaD
Dobutamine—Headache—Etoposide—urinary bladder cancer	0.00207	0.00445	CcSEcCtD
Dobutamine—Chest pain—Methotrexate—urinary bladder cancer	0.00206	0.00444	CcSEcCtD
Dobutamine—Palpitations—Epirubicin—urinary bladder cancer	0.002	0.00431	CcSEcCtD
Dobutamine—Nausea—Etoposide—urinary bladder cancer	0.00196	0.00422	CcSEcCtD
Dobutamine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00193	0.00417	CcSEcCtD
Dobutamine—Chest pain—Epirubicin—urinary bladder cancer	0.00193	0.00416	CcSEcCtD
Dobutamine—Palpitations—Doxorubicin—urinary bladder cancer	0.00185	0.00399	CcSEcCtD
Dobutamine—Hypotension—Methotrexate—urinary bladder cancer	0.00185	0.00398	CcSEcCtD
Dobutamine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00181	0.0039	CcSEcCtD
Dobutamine—Tachycardia—Epirubicin—urinary bladder cancer	0.0018	0.00389	CcSEcCtD
Dobutamine—Chest pain—Doxorubicin—urinary bladder cancer	0.00178	0.00385	CcSEcCtD
Dobutamine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00176	0.0038	CcSEcCtD
Dobutamine—Hypotension—Epirubicin—urinary bladder cancer	0.00173	0.00372	CcSEcCtD
Dobutamine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.00167	0.00361	CcSEcCtD
Dobutamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00167	0.0036	CcSEcCtD
Dobutamine—Dyspnoea—Epirubicin—urinary bladder cancer	0.00165	0.00355	CcSEcCtD
Dobutamine—Hypotension—Doxorubicin—urinary bladder cancer	0.0016	0.00344	CcSEcCtD
Dobutamine—CA5A—Metabolism—GSTZ1—urinary bladder cancer	0.00158	0.00677	CbGpPWpGaD
Dobutamine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00152	0.00329	CcSEcCtD
Dobutamine—CA5A—Metabolism—GSTO2—urinary bladder cancer	0.0015	0.00642	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—NAT1—urinary bladder cancer	0.0015	0.00642	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GSTZ1—urinary bladder cancer	0.00148	0.00632	CbGpPWpGaD
Dobutamine—COMT—Biological oxidations—GSTP1—urinary bladder cancer	0.00143	0.00613	CbGpPWpGaD
Dobutamine—COMT—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00141	0.00604	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GSTO2—urinary bladder cancer	0.0014	0.00599	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—NAT1—urinary bladder cancer	0.0014	0.00599	CbGpPWpGaD
Dobutamine—Pruritus—Methotrexate—urinary bladder cancer	0.0014	0.00301	CcSEcCtD
Dobutamine—CA5A—Metabolism—UGT2B7—urinary bladder cancer	0.00137	0.00587	CbGpPWpGaD
Dobutamine—COMT—Biological oxidations—GSTM1—urinary bladder cancer	0.00132	0.00563	CbGpPWpGaD
Dobutamine—ADRB2—Arf6 trafficking events—CDH1—urinary bladder cancer	0.00131	0.00562	CbGpPWpGaD
Dobutamine—Pruritus—Epirubicin—urinary bladder cancer	0.00131	0.00282	CcSEcCtD
Dobutamine—COMT—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.0013	0.00555	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—UGT2B7—urinary bladder cancer	0.00128	0.00548	CbGpPWpGaD
Dobutamine—Headache—Methotrexate—urinary bladder cancer	0.00124	0.00267	CcSEcCtD
Dobutamine—CA5A—Metabolism—CYP4B1—urinary bladder cancer	0.00124	0.00529	CbGpPWpGaD
Dobutamine—Pruritus—Doxorubicin—urinary bladder cancer	0.00121	0.00261	CcSEcCtD
Dobutamine—Nausea—Methotrexate—urinary bladder cancer	0.00117	0.00253	CcSEcCtD
Dobutamine—CA5A—Metabolism—SLC19A1—urinary bladder cancer	0.00117	0.00499	CbGpPWpGaD
Dobutamine—Headache—Epirubicin—urinary bladder cancer	0.00116	0.0025	CcSEcCtD
Dobutamine—CA5B—Metabolism—CYP4B1—urinary bladder cancer	0.00115	0.00494	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PRSS3—urinary bladder cancer	0.00114	0.00487	CbGpPWpGaD
Dobutamine—ADRB2—Arf6 signaling events—SRC—urinary bladder cancer	0.00111	0.00475	CbGpPWpGaD
Dobutamine—Nausea—Epirubicin—urinary bladder cancer	0.0011	0.00237	CcSEcCtD
Dobutamine—CA5B—Metabolism—SLC19A1—urinary bladder cancer	0.00109	0.00466	CbGpPWpGaD
Dobutamine—Headache—Doxorubicin—urinary bladder cancer	0.00107	0.00231	CcSEcCtD
Dobutamine—CA5B—Metabolism—PRSS3—urinary bladder cancer	0.00106	0.00454	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GSTZ1—urinary bladder cancer	0.00105	0.00448	CbGpPWpGaD
Dobutamine—Nausea—Doxorubicin—urinary bladder cancer	0.00102	0.00219	CcSEcCtD
Dobutamine—CA2—Metabolism—GSTO2—urinary bladder cancer	0.000993	0.00425	CbGpPWpGaD
Dobutamine—CA2—Metabolism—NAT1—urinary bladder cancer	0.000993	0.00425	CbGpPWpGaD
Dobutamine—ADRB2—Arf6 signaling events—EGFR—urinary bladder cancer	0.000972	0.00416	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—TYMP—urinary bladder cancer	0.00091	0.00389	CbGpPWpGaD
Dobutamine—CA2—Metabolism—UGT2B7—urinary bladder cancer	0.000908	0.00388	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GSTZ1—urinary bladder cancer	0.000878	0.00375	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—TYMP—urinary bladder cancer	0.000849	0.00363	CbGpPWpGaD
Dobutamine—COMT—Metabolism—NAT1—urinary bladder cancer	0.000832	0.00356	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GSTO2—urinary bladder cancer	0.000832	0.00356	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—NAT2—urinary bladder cancer	0.000823	0.00352	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CYP4B1—urinary bladder cancer	0.000818	0.0035	CbGpPWpGaD
Dobutamine—CA2—Metabolism—SLC19A1—urinary bladder cancer	0.000772	0.0033	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—NAT2—urinary bladder cancer	0.000768	0.00328	CbGpPWpGaD
Dobutamine—COMT—Metabolism—UGT2B7—urinary bladder cancer	0.000761	0.00325	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PRSS3—urinary bladder cancer	0.000752	0.00322	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—RRM2—urinary bladder cancer	0.00071	0.00304	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CYP4B1—urinary bladder cancer	0.000685	0.00293	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—RRM2—urinary bladder cancer	0.000663	0.00284	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ENO2—urinary bladder cancer	0.000658	0.00281	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—HPGDS—urinary bladder cancer	0.000658	0.00281	CbGpPWpGaD
Dobutamine—COMT—Metabolism—SLC19A1—urinary bladder cancer	0.000647	0.00277	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GSTT1—urinary bladder cancer	0.000638	0.00273	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PRSS3—urinary bladder cancer	0.00063	0.0027	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—ENO2—urinary bladder cancer	0.000614	0.00263	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—HPGDS—urinary bladder cancer	0.000614	0.00263	CbGpPWpGaD
Dobutamine—CA2—Metabolism—TYMP—urinary bladder cancer	0.000601	0.00257	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GSTT1—urinary bladder cancer	0.000595	0.00255	CbGpPWpGaD
Dobutamine—CA2—Metabolism—NAT2—urinary bladder cancer	0.000544	0.00233	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—NQO1—urinary bladder cancer	0.00053	0.00227	CbGpPWpGaD
Dobutamine—COMT—Metabolism—TYMP—urinary bladder cancer	0.000504	0.00216	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—NQO1—urinary bladder cancer	0.000495	0.00212	CbGpPWpGaD
Dobutamine—CA2—Metabolism—RRM2—urinary bladder cancer	0.00047	0.00201	CbGpPWpGaD
Dobutamine—COMT—Metabolism—NAT2—urinary bladder cancer	0.000456	0.00195	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GSTP1—urinary bladder cancer	0.000442	0.00189	CbGpPWpGaD
Dobutamine—CA2—Metabolism—HPGDS—urinary bladder cancer	0.000435	0.00186	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ENO2—urinary bladder cancer	0.000435	0.00186	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GSTT1—urinary bladder cancer	0.000422	0.0018	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GSTP1—urinary bladder cancer	0.000413	0.00177	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—TYMS—urinary bladder cancer	0.000411	0.00176	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GSTM1—urinary bladder cancer	0.000406	0.00174	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—NCOR1—urinary bladder cancer	0.000406	0.00174	CbGpPWpGaD
Dobutamine—COMT—Metabolism—RRM2—urinary bladder cancer	0.000393	0.00168	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GPX1—urinary bladder cancer	0.000389	0.00166	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—TYMS—urinary bladder cancer	0.000384	0.00164	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ERCC2—urinary bladder cancer	0.000382	0.00163	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—NCOR1—urinary bladder cancer	0.000379	0.00162	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GSTM1—urinary bladder cancer	0.000379	0.00162	CbGpPWpGaD
Dobutamine—COMT—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000374	0.0016	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ENO2—urinary bladder cancer	0.000364	0.00156	CbGpPWpGaD
Dobutamine—COMT—Metabolism—HPGDS—urinary bladder cancer	0.000364	0.00156	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GPX1—urinary bladder cancer	0.000363	0.00155	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—MTHFR—urinary bladder cancer	0.000359	0.00154	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—ERCC2—urinary bladder cancer	0.000357	0.00153	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GSTT1—urinary bladder cancer	0.000353	0.00151	CbGpPWpGaD
Dobutamine—CA2—Metabolism—NQO1—urinary bladder cancer	0.000351	0.0015	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—MTHFR—urinary bladder cancer	0.000335	0.00143	CbGpPWpGaD
Dobutamine—COMT—Metabolism—NQO1—urinary bladder cancer	0.000294	0.00126	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GSTP1—urinary bladder cancer	0.000292	0.00125	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PPARG—urinary bladder cancer	0.000291	0.00125	CbGpPWpGaD
Dobutamine—COMT—Neuronal System—HRAS—urinary bladder cancer	0.000287	0.00123	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—CREBBP—urinary bladder cancer	0.00028	0.0012	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PPARG—urinary bladder cancer	0.000272	0.00116	CbGpPWpGaD
Dobutamine—CA2—Metabolism—TYMS—urinary bladder cancer	0.000272	0.00116	CbGpPWpGaD
Dobutamine—CA2—Metabolism—NCOR1—urinary bladder cancer	0.000269	0.00115	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GSTM1—urinary bladder cancer	0.000269	0.00115	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000266	0.00114	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—CREBBP—urinary bladder cancer	0.000261	0.00112	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HDAC4—urinary bladder cancer	0.00026	0.00111	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GPX1—urinary bladder cancer	0.000257	0.0011	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ERCC2—urinary bladder cancer	0.000253	0.00108	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GSTP1—urinary bladder cancer	0.000245	0.00105	CbGpPWpGaD
Dobutamine—CA2—Metabolism—MTHFR—urinary bladder cancer	0.000237	0.00102	CbGpPWpGaD
Dobutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000236	0.00101	CbGpPWpGaD
Dobutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000231	0.000986	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PTGS2—urinary bladder cancer	0.000229	0.00098	CbGpPWpGaD
Dobutamine—COMT—Metabolism—TYMS—urinary bladder cancer	0.000228	0.000974	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GSTM1—urinary bladder cancer	0.000225	0.000963	CbGpPWpGaD
Dobutamine—COMT—Metabolism—NCOR1—urinary bladder cancer	0.000225	0.000963	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GLI1—urinary bladder cancer	0.000223	0.000953	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GLI1—urinary bladder cancer	0.000218	0.000932	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GPX1—urinary bladder cancer	0.000216	0.000922	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PTGS2—urinary bladder cancer	0.000214	0.000915	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ERCC2—urinary bladder cancer	0.000212	0.000905	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PTEN—urinary bladder cancer	0.0002	0.000854	CbGpPWpGaD
Dobutamine—COMT—Metabolism—MTHFR—urinary bladder cancer	0.000199	0.000851	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PPARG—urinary bladder cancer	0.000193	0.000823	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—EP300—urinary bladder cancer	0.00019	0.000815	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PTEN—urinary bladder cancer	0.000186	0.000798	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CREBBP—urinary bladder cancer	0.000185	0.000791	CbGpPWpGaD
Dobutamine—ADRB1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000179	0.000768	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—EP300—urinary bladder cancer	0.000178	0.000761	CbGpPWpGaD
Dobutamine—ADRB2—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000176	0.000751	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PPARG—urinary bladder cancer	0.000161	0.00069	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CREBBP—urinary bladder cancer	0.000155	0.000663	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—RBX1—urinary bladder cancer	0.000153	0.000653	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PTGS2—urinary bladder cancer	0.000151	0.000648	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—RBX1—urinary bladder cancer	0.000149	0.000639	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TSC1—urinary bladder cancer	0.000144	0.000614	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TSC1—urinary bladder cancer	0.00014	0.000601	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—JAG1—urinary bladder cancer	0.000137	0.000585	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—JAG1—urinary bladder cancer	0.000134	0.000572	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PTEN—urinary bladder cancer	0.000132	0.000565	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PTGS2—urinary bladder cancer	0.000127	0.000543	CbGpPWpGaD
Dobutamine—CA2—Metabolism—EP300—urinary bladder cancer	0.000126	0.000539	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000116	0.000494	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000113	0.000483	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PTEN—urinary bladder cancer	0.000111	0.000473	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—S100B—urinary bladder cancer	0.000111	0.000473	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—S100B—urinary bladder cancer	0.000108	0.000463	CbGpPWpGaD
Dobutamine—COMT—Metabolism—EP300—urinary bladder cancer	0.000106	0.000451	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—RHOA—urinary bladder cancer	0.000105	0.000449	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—RHOA—urinary bladder cancer	0.000103	0.000439	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000101	0.000434	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NCOR1—urinary bladder cancer	9.95e-05	0.000426	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.92e-05	0.000424	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NCOR1—urinary bladder cancer	9.73e-05	0.000416	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—IL2—urinary bladder cancer	9.69e-05	0.000415	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—IL2—urinary bladder cancer	9.48e-05	0.000406	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—CXCL8—urinary bladder cancer	9.21e-05	0.000394	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—CXCL8—urinary bladder cancer	9.01e-05	0.000385	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—IL2—urinary bladder cancer	8.8e-05	0.000377	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TERT—urinary bladder cancer	8.77e-05	0.000375	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—IL2—urinary bladder cancer	8.61e-05	0.000368	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TERT—urinary bladder cancer	8.58e-05	0.000367	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGFR3—urinary bladder cancer	8.05e-05	0.000344	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGFR3—urinary bladder cancer	7.87e-05	0.000337	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	7.82e-05	0.000334	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	7.65e-05	0.000327	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	6.85e-05	0.000293	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	6.77e-05	0.000289	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	6.73e-05	0.000288	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	6.7e-05	0.000287	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	6.62e-05	0.000283	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	6.59e-05	0.000282	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	6.36e-05	0.000272	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	6.22e-05	0.000266	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	6.2e-05	0.000265	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	6.06e-05	0.000259	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	5.74e-05	0.000245	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	5.61e-05	0.00024	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	5.44e-05	0.000233	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	5.41e-05	0.000231	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	5.32e-05	0.000228	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	5.29e-05	0.000226	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	5.2e-05	0.000222	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	5.09e-05	0.000218	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	5.07e-05	0.000217	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	4.96e-05	0.000212	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	4.92e-05	0.000211	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.9e-05	0.00021	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	4.89e-05	0.000209	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	4.81e-05	0.000206	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	4.8e-05	0.000205	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	4.79e-05	0.000205	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	4.67e-05	0.0002	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	4.56e-05	0.000195	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	4.54e-05	0.000194	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	4.44e-05	0.00019	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	4.07e-05	0.000174	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	3.98e-05	0.00017	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	3.98e-05	0.00017	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	3.89e-05	0.000166	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	3.76e-05	0.000161	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	3.68e-05	0.000157	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	3.34e-05	0.000143	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	3.27e-05	0.00014	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	3.19e-05	0.000137	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	3.12e-05	0.000134	CbGpPWpGaD
